Thrombotic thrombocytopenic purpura (TTP)

What is thrombotic thrombocytopenic purpura (TTP)?

Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening blood disorder. It is characterized by the formation of small blood clots (microthrombi) throughout the body. These microthrombi can block small blood vessels and damage organs, such as the brain, kidneys, and heart.

TTP is caused by a deficiency of a protein called ADAMTS13. ADAMTS13 is responsible for cleaving a large protein called von Willebrand factor (VWF). When ADAMTS13 is deficient, VWF forms large multimers that can clump together to form microthrombi.

There are two main types of TTP:

  • Acquired: This is the most common type of TTP and is caused by an autoimmune disorder. In autoimmune disorders, the body’s immune system attacks its own tissues. In acquired TTP, the immune system attacks ADAMTS13.
  • Congenital: This is caused by a genetic mutation that affects the ADAMTS13 gene and is rare.

What are the related clinical signs and symptoms?

TTP has traditionally been described as the pentad of thrombocytopenia, microangiopathic haemolytic anemia, neurologic abnormalities, renal failure and fever. The microvascular thrombosis causes variable degrees of tissue ischaemia and infarction and is responsible for the microangiopathic hemolytic anemia and thrombocytopenia.

The clinical manifestations of this disorder depend on the severity of the disease and the organs that are affected. The most common clinical manifestations include:

  • Thrombocytopenia
  • Microangiopathic hemolytic anemia (MAHA)
  • Neurologic signs and symptoms, such as headache, confusion, seizures, and focal neurologic deficits
  • Renal failure
  • Fever
  • Fatigue
  • Pallor

How does TTP occur?

This disorder occurs in familial or acquired forms. 

There is a deficiency of ADAMTS13 metalloprotease which breaks down ultra large von Willebrand factor multimers. In the inherited forms, there are more than 50 ADAMTS13 mutations and the acquired forms follow the development of an inhibitory IgG autoantibody which may be stimulated by infection, autoimmune or connective tissue disease, certain drugs, stem cell transplantation or cardiac surgery. 

Ultra large vWF multimeric strings secreted from Weibel-Palade bodies are anchored to the endothelial cells and passing platelets adhere via their GP1bɑ receptors. Increasing platelet aggregation onto the ULVWF multimeric strings has the potential to form large, occlusive, platelet thrombi. These strings are capable of embolising to microvessels downstream contributing to organ ischaemia. 

Under physiological circumstances a metalloprotease ADAMTS13 cleaves high molecular weight multimers at a Tyr-842-Met-843 bond, resulting in vWF with a molecular weight of 500 – 20000 kDA. In acquired TTP, an antibody develops against the metalloprotease and impedes the cleavage of vWF multimers while in congenital TTP, the protease is absent. 

How do we investigate TTP?

  • Complete blood count (CBC): A CBC measures the levels of red blood cells, white blood cells, and platelets in the blood. In TTP, the CBC will typically show thrombocytopenia (low platelet count) and microangiopathic hemolytic anemia (MAHA), a type of anemia characterized by the presence of fragmented red blood cells (schistocytes).
  • Peripheral blood smear: A peripheral blood smear is a microscopic examination of the blood cells. In TTP, the peripheral blood smear will typically show schistocytes.
  • ADAMTS13 activity assay: The ADAMTS13 activity assay measures the level of ADAMTS13 in the blood. ADAMTS13 is a protein that cleaves von Willebrand factor (VWF), a large protein that plays a role in blood clotting. In TTP, the ADAMTS13 activity level is typically low.
  • ADAMTS13 inhibitor assay: The ADAMTS13 inhibitor assay detects the presence of autoantibodies that inhibit ADAMTS13 activity. Autoantibodies are antibodies that are produced by the body’s own immune system against its own tissues or cells. In acquired TTP, the most common type of TTP, autoantibodies against ADAMTS13 are present in the blood.

In current clinical practice, thrombocytopenia, schistocytosis and an impressively elevated serum LDH are sufficient to suggest the diagnosis. The bone marrow is hypercellular with erythroid hyperplasia. Coagulation tests are normal. ADAMTS13 is absent or severely reduced in plasma. 

What is the treatment and management for TTP?

The treatment and management of thrombotic thrombocytopenic purpura (TTP) is aimed at increasing the levels of ADAMTS13 in the blood and preventing the formation of microthrombi. The mainstay of treatment is plasma exchange, a procedure in which the plasma (liquid portion of the blood) is removed and replaced with fresh plasma from a donor. Plasma exchange provides a source of ADAMTS13 and also removes autoantibodies that may be inhibiting ADAMTS13 activity.

Other treatments that may be used include:

  • Corticosteroids: Corticosteroids can suppress the immune system and reduce inflammation. Corticosteroids are often used in conjunction with plasma exchange in patients with acquired TTP.
  • Rituximab: Rituximab is a monoclonal antibody that targets and destroys B cells, which are the type of white blood cell that produces autoantibodies. Rituximab may be used in patients with acquired TTP who have a high risk of relapse, or in patients who do not respond to plasma exchange and corticosteroids.
  • Caplacizumab: Caplacizumab is a monoclonal antibody that targets and blocks von Willebrand factor (VWF), preventing platelet aggregation and microthrombus formation. Caplacizumab is a newer treatment that has been shown to be effective in reducing the mortality rate of TTP.

Below is the synopsis of thrombotic thrombocytopenic purpura (TTP).


Thrombocytopenia due to deficiency of ADAMTS13 metalloprotease which leads to formation of platelet thrombi in microvessels. 

Signs and symptoms (pentad)

  • Thrombocytopenia
  • Microangiopathic hemolysis
  • Neurologic dysfunction
  • Renal impairment
  • Fever


  • Inherited mutations
  • Acquired: inhibitory IgG autoantibodies stimulated by infection, autoimmune/connective tissue disease, drugs, stem cell transplantation or cardiac surgery


Unveiling the Mechanism of TTP: A Microscopic Look at ADAMTS-13 Deficiency and Platelet Aggregation - Illustrates the absence of ADAMTS-13, a crucial enzyme, leading to platelet aggregation and blood clot formation in thrombotic thrombocytopenic purpura (TTP).
ADAMTS-13: The Missing Link in Blood Vessel Integrity
ADAMTS-13, an enzyme responsible for cleaving large von Willebrand factor (VWF) multimers, plays a pivotal role in maintaining the delicate balance of blood vessel integrity. In TTP, the absence of ADAMTS-13 leads to an accumulation of these large VWF multimers, creating a sticky environment that promotes platelet aggregation.

Laboratory investigations

Full blood count and peripheral blood characteristics

Full blood count: Thrombocytopenia 

Peripheral blood smear: Schistocytosis

Bone marrow characteristics

Markedly hypercellular with erythroid hyperplasia

Other important investigations and expected results

  • ↑↑ serum LDH
  • Coagulation tests normal 
  • Specific assay: ADAMTS-13 ↓↓ or absent

Treatment and management of TTP

Related Diseases

Activated Partial Thromboplastin Time (aPTT)

Activated Partial Thromboplastin Time (aPTT)

Introduction The activated partial thromboplastin time (APTT) assay is a blood test that measures how long it takes for a blood clot to form. It is one of the most common blood tests performed, and it is used to diagnose and monitor a variety of bleeding and clotting...

Prothrombin Time (PT)

Prothrombin Time (PT)

Introduction The prothrombin time (PT) assay is a blood test that measures how long it takes for a blood clot to form. It is one of the most common blood tests performed in the world, and it is used to diagnose and monitor a variety of bleeding and clotting disorders....